首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   30093篇
  免费   3207篇
  国内免费   762篇
耳鼻咽喉   230篇
儿科学   1042篇
妇产科学   4007篇
基础医学   3995篇
口腔科学   455篇
临床医学   2938篇
内科学   2353篇
皮肤病学   210篇
神经病学   1142篇
特种医学   676篇
外国民族医学   17篇
外科学   1976篇
综合类   4600篇
现状与发展   2篇
预防医学   3210篇
眼科学   201篇
药学   1951篇
  10篇
中国医学   1361篇
肿瘤学   3686篇
  2024年   38篇
  2023年   685篇
  2022年   776篇
  2021年   1216篇
  2020年   988篇
  2019年   919篇
  2018年   1034篇
  2017年   899篇
  2016年   1302篇
  2015年   1576篇
  2014年   2188篇
  2013年   2145篇
  2012年   1713篇
  2011年   1641篇
  2010年   1472篇
  2009年   1384篇
  2008年   1274篇
  2007年   1160篇
  2006年   1121篇
  2005年   1086篇
  2004年   1234篇
  2003年   748篇
  2002年   654篇
  2001年   583篇
  2000年   454篇
  1999年   351篇
  1998年   387篇
  1997年   453篇
  1996年   478篇
  1995年   413篇
  1994年   508篇
  1993年   354篇
  1992年   383篇
  1991年   374篇
  1990年   319篇
  1989年   246篇
  1988年   254篇
  1987年   136篇
  1986年   152篇
  1985年   153篇
  1984年   153篇
  1983年   104篇
  1982年   138篇
  1981年   110篇
  1980年   67篇
  1979年   61篇
  1978年   42篇
  1977年   41篇
  1976年   31篇
  1975年   19篇
排序方式: 共有10000条查询结果,搜索用时 93 毫秒
31.
目的探讨紫杉醇联合卡铂化疗治疗卵巢癌的效果分析。方法选自2018年5月-2019年5月132名符合入组以及排除标准的患者,随后研究人员将患者分为对照组以及研究组,分组应按照科学、合理、随机的标准,两组患者分别均有67例,对照组患者按照研究要求,接受卡铂化疗治疗,研究组患者按照研究要求,接受紫杉醇联合卡铂化疗治疗,两组患者分别接受不同的治疗,评估患者的临床效果,对比两组患者的观察指标,如:T细胞亚群、临床疗效。结果治疗后,CD8、CD4、CD3、CD4/CD8,研究组高于对照组;研究组中,CR+PR+SD人数多于对照组患者,且治疗总有效率高于对照组患者(P<0.05)。结论紫杉醇联合卡铂化疗治疗卵巢癌,能够提升患者自身的免疫功能,促进疾病的好转。  相似文献   
32.
Objective To analyze the early mortality and related risk factors of new hemodialysis patients in Zhejiang province, and provide basis for reducing the death risk of hemodialysis patients. Methods The early mortality and related factors of new hemodialysis patients from January 1, 2010 to June 30, 2018 were retrospectively analyzed using the database of Zhejiang province hemodialysis registration. The early mortality was defined as death within 90 days of dialysis. Cox regression model was used to analyze the related risk factors of the early mortality in hemodialysis patients. Results The mortality was the highest in the first month after dialysis (46.40/100 person year), and gradually stabilized after three months. The early mortality was 25.33/100 person year. The mortality within 120 days and 360 days were 21.40/100 person year and 11.37/100 person year, respectively. The elderly (≥65 years old, HR=1.981, 95%CI 1.319-2.977, P<0.001), primary tumor (HR=3.308, 95%CI 1.137-5.624, P=0.028), combined with tumors (not including the primary tumor, HR=2.327, 95%CI 1.200-4.513, P=0.012), temporary catheter (the initial dialysis pathway, HR=3.632, 95%CI 1.806-7.307, P<0.001), lower albumin (<30 g/L, HR=2.181, 95%CI 1.459-3.260, P<0.001), lower hemoglobin (every 0.01 g/L increase, HR=0.861, 95%CI 0.793-0.935, P=0.001), lower high density lipoprotein (<0.7 mmol/L, HR=1.796, 95%CI 1.068-3.019, P=0.027) and higher C reactive protein (≥40 mg/L, HR=1.889, 95%CI 1.185-3.012, P=0.008) were the risk factors of early death for hemodialysis patients. Conclusions The early mortality of hemodialysis patients is high after dialysis, and gradually stable after 3 months. The elderly, primary tumor, combined with tumors, the initial dialysis pathway, lower albumin, lower hemoglobin, lower high density lipoprotein and higher C reactive protein are the risk factors of early death for hemodialysis patients.  相似文献   
33.
Although psychoanalysis was the first-choice treatment for premature ejaculation (PE) between 1920 and 1960, hardly any reports on its efficacy have been published. Moreover, a scientific debate about its findings has never been fully developed. The recent progress that has been made in the classification of three different PE syndromes creates a new opportunity for psychoanalytic investigations of men with complaints of PE, distinguished by the actual duration of their intravaginal ejaculation latency time (IELT). The term premature-like ejaculatory dysfunction has been introduced to distinguish men with self-perceived PE at normal and long IELT durations from those men with lifelong, acquired and normal variable PE. Psychoanalytic research may contribute to a better understanding of the consequences of objective early ejaculations on the unconscious mental life of men with the four forms of PE. By integrating neurobiological, clinical and epidemiological data of ejaculatory performance, a revival of psychoanalytic research of PE in the four distinct, classified PE groups, will probably contribute to a deeper insight in to the unconscious mental life of men affected by PE.  相似文献   
34.
目的观察美托康注射液与都可喜联合治疗椎基底动脉供血不足的临床疗效。方法随机将87例病人分为治疗组(45例)和对照组(42例),治疗组应用美托康注射液250ml静滴,1a/d,同时加服都可喜1片,2次/d;对照组应用复方丹参注射液30m1加入5%葡萄糖注射液500ml静滴,1次/d;两组均连用10d,其余常规治疗相同。结果治疗组痊愈26例,有效18例,总有效率98%;对照组痊愈15例,有效24例,总有效率93%。治疗组疗效优于对照组(P〈0.05)。结论美托康注射液与都可喜联合治疗椎基底动脉供血不足有良好临床疗效,可于临床广泛应用。  相似文献   
35.
The objective of this study was to assess the implication of copy number changes of epidermal growth factor receptor (EGFR) and erbB2 genes in the etiology and progression of ovarian tumors. In our study, we used the highly reliable method of fluorescent in situ hybridization, applied on tissue microarray, containing 1006 ovarian tumors from different malignancy, histologic type and grade, and tumor stage, in order to analyze the correlations between gene copy number changes and tumor phenotype. We established copy number changes of erbB2 in 15.30% of malignant ovarian tumors-8.16% amplifications and 7.14% gains. The frequency of EGFR copy number changes was 10.67%-3.65% amplifications and 7.02% gains. EGFR gains occurred with approximately the same frequency in malignant (7.02%), low malignant potential (8.33%), and benign (7.19%) ovarian tumors. ErbB2 amplification was associated with clear cell type of ovarian cancer (P < 0.04). No amplification of EGFR and erbB2 genes was established in tumors with low malignant potency and in benign tumors. Regarding cancer phenotype, there was no statistically significant association between erbB2 copy number changes and histologic grade as well as tumor stage of ovarian cancer. EGFR gains are early events in ovarian tumorigenesis. Our results showed similar frequencies of EGFR gains in different grade tumors, while EGFR amplification increased from grades 1 to 2 to 3.  相似文献   
36.
37.
The purpose of this study was to compare prognostic models evaluating the probability of an ovarian cancer occurrence based on a number of clinical and ultrasonographic data in women with adnexal masses. A total of 686 women with adnexal masses underwent the examinations between 1994 and 2002. The recorded parameters included: age, menopausal status, body mass index, the grayscale and Doppler ultrasonographic examination, and selected markers concentration levels. In order to find the best combination of features, which significantly influences the probability of malignancy, stepwise logistic regression analysis, as well as artificial neural network, was used. The diagnostic efficiency of received models was estimated and compared using receiver-operating characteristics (ROC) curve. The results indicate that 431 and 255 patients had a benign and malignant ovarian tumor, respectively. Application of stepwise logistic regression analysis revealed statistically significant importance of eight features. The sensitivity and specificity for the received model were 65.71% and 77.59%, respectively. Three-layer perceptron network shows 13 features as significant predictors of malignancy. The network gave a sensitivity of 85.7% and specificity of 93.1%. Comparison of area under ROC curve for received models was 0.9679 vs 0.9716. Prognostic values of the analyzed neural model are not optimal but seem to surpass logistic regression model in terms of the predictive possibilities.  相似文献   
38.
39.
Gonadotropins have been implicated in the development of epithelial ovarian cancers. These tumors are derived from ovarian surface epithelium (OSE). The purpose of this study was to determine the effects of these hormones on DNA synthesis and spontaneous cell death in primary cultures of OSE and three immortalized OSE cultures. Primary cultures of OSE cells were generated from the ovaries of women with benign disease. The effects of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) on DNA synthesis and cell death were determined using [(3)H]thymidine incorporation and JAM assays. Significant inductions of DNA synthesis were demonstrated with LH in 4/12 (33%) primary cultures of OSE and 2/3 OSE cell lines and with FSH in 4/11 (36%) primary cultures of OSE and 2/3 OSE cell lines. A significant protection from cell death was also observed in the presence of FSH in 2/4 primary cultures of OSE and 1/3 OSE cell lines and in the presence of LH in 1/4 primary cultures of OSE and 2/3 OSE cell lines. The results indicate that while gonadotropins have the potential to induce cell proliferation and protect from cell death in OSE cells in vitro, their effects are variable in OSE cells from different women.  相似文献   
40.
Abstract.   Gurbuz A, Karateke A, Kabaca C, Kir G, Cetingoz E. Peritoneal tuberculosis simulating advanced ovarian carcinoma: is clinical impression sufficient to administer neoadjuvant chemotherapy for advanced ovarian cancer? Int J Gynecol Cancer 2006; 16(Suppl. 1): 307–312.
Peritoneal tuberculosis mimics advanced ovarian cancer because of the similarities in clinical signs and symptoms such as ascites, pelvic and abdominal pain and mass, and elevation of serum CA125 level. We have presented four cases of peritoneal tuberculosis that underwent exploratory laparotomy for suspected advanced ovarian cancer during a 3-year period. Definitive diagnosis of tuberculosis was performed at laparotomy in all the cases. The frozen-section analysis seems to be the gold standard in the differential diagnosis. In view of these data, clinical diagnosis of advanced ovarian cancer is not sufficient for administering neoadjuvant chemotherapy. Cytologic or pathologic findings must be consistent with ovarian cancer for candidates who are being considered for neoadjuvant chemotherapy.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号